Atrial Fibrillation Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 65 or older, OR people aged 50 or older who also meet at least one of these additional conditions: a specific heart protein level above 400 pg/mL on a blood test (NT-proBNP), an enlarged upper-left chamber of the heart detected on imaging, or silent brain damage found in more than one blood vessel area of the brain
- People who are willing and able to give written consent to participate
- People who have silent (symptom-free) signs of reduced blood flow to the brain found on a brain scan, which may appear in one of several specific patterns — including areas of recent restricted blood flow, small fluid-filled cavities of a certain shape and size, or patches of abnormal brain tissue signal on MRI — and where these findings are not explained by multiple sclerosis, serious past head injury, radiation, certain drug effects, or carbon monoxide poisoning (confirm with trial site for exact scan criteria)
Who may not be able to join:
- People who have a history of atrial fibrillation or atrial flutter (irregular heart rhythms)
- People who have had symptoms of an acute stroke (though people with silent or unnoticed neurological changes may still be considered)
- People who already have a pacemaker, implantable heart defibrillator, or implantable heart monitor
- People for whom a doctor has determined that a pacemaker, implantable defibrillator, or implantable heart monitor is needed
- People who have had, or are recommended to have, major heart surgery or a transcatheter heart valve procedure
- People for whom long-term blood-thinning medication (anticoagulation) is already recommended or indicated
- People for whom long-term blood-thinning medication is not safe to use
- People whose life expectancy is estimated to be less than 2 years
- People with an active, high-grade cancer inside or outside the brain
- People who are already enrolled in another clinical trial that could interfere with this study's goals
- People who are unable to understand the nature, purpose, and consequences of the study, or to make their own informed decisions about participation
- People who are unable to follow the study procedures, for example due to language barriers, psychological conditions, or dementia
- People with known or suspected issues with non-compliance, or with drug or alcohol misuse
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Laurent Roten, PD Dr. med., Inselgruppe AG
Phone: +41 31 632 52 63
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Cumulative incidence of Arterial Fibrillation (AF) diagnosis over a median of 24 months
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.